Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
An accomplished R&D leader and champion of the application of AI to drug discovery
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Automated parallel capillary electrophoresis system simplifies protein analysis
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
Subscribe To Our Newsletter & Stay Updated